プラズモディアム選択性プロテアソーム阻害剤の構造と機能に基づく設計
Hao Li1,2, Anthony J O'Donoghue3, Wouter A van der Linden1
1Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California 94305, USA.
Nature
|February 12, 2016
まとめ
研究者はマラリア治療のために 選択性プロテアソーム阻害剤を開発しました これらの化合物はプラズモディウムプロテアソームを標的とし,薬剤耐性寄生虫に対する有効性を示し,宿主に対する毒性が最小限であり,有望な新しい抗マラリア戦略を提供します.
科学分野:
- 生物化学
- 寄生虫学
- 薬物の発見
背景:
- プロテアソームは 細胞の重要なプロセスを制御し 病原体治療のターゲットとなります
- プロテアソーム阻害剤は,マラリア寄生虫プラズモディウムファルシパラムに対する毒性を示しています.
- 既存の阻害剤は選択性がなく,寄生虫と宿主タンパク質の両方に影響を及ぼし,治療用途を制限しています.
研究 の 目的:
- 選択的阻害剤の開発のためのプラズモジアムプロテアソーム基板特異性と構造的特性を定義する.
- 人間とPlasmodium falciparumのプロテアソームの特異性を特定する.
- 抗マラリア剤として寄生虫選択性プロテアソーム阻害剤の開発と検証
主な方法:
- ヒトとプラズモディウムタンパク質の特異性を比較するための基板プロファイリング.
- プラズモディウム特有のアミノ酸偏好を標的とする阻害剤の設計
- 低温電子顕微鏡で,プラズモディウムタンパク質が阻害剤に結合する構造を決定する.
- 阻害剤の効能と毒性のインビトロおよびインビボ試験
主要な成果:
- ヒトとプラズモディウムタンパク質の 異なる基板特異性を特定した.
- プラズモジアムタンパク質のβ2サブユニットを標的とした選択的阻害剤を開発した.
- プラズモジアムタンパク質の3. 6 Åの冷凍EM構造を決定し,開いたβ2活性部位を明らかにした.
- アーテミシニンと寄生虫の相乗効果の抑制が実証され,宿主毒性がない.
結論:
- プラズモディアム・プロテアゾームは マラリアの有効かつ選択的な薬標的である.
- 寄生虫選択性阻害剤は 次世代の抗マラリア治療薬として 潜在性を示しています
- プラズモジアムタンパク質の構造的な洞察は,合理的な阻害剤の設計を容易にする.
さらに関連する動画
09:13Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
Published on: November 22, 2024
1.6K
10:38High Yield Purification of Plasmodium falciparum Merozoites For Use in Opsonizing Antibody Assays
Published on: July 17, 2014
23.4K
関連する概念動画
Diversity of Protists II
589
Alveolates are a group of organisms recognized by the presence of alveoli, which are cytoplasmic sacs located beneath the cell membrane. While their function remains uncertain, alveoli may help regulate water balance by controlling how much water enters and leaves the cell. In dinoflagellates, these structures may serve as armor plates. There are three major types of alveolates: ciliates, which move using cilia; dinoflagellates, which use flagella for movement; and apicomplexans, which are...
589
Overview of Protists
868
Protists are diverse eukaryotic microorganisms that lack the specialized tissues of plants and animals and the chitinous cell walls of fungi. Their early divergence within Eukarya resulted in structural, functional, and ecological diversity. They are classified into supergroups such as Archaeplastida, Excavata, Amoebozoa, Rhizaria, Alveolata, and Stramenopiles, determined through genetic analysis and structural similarities.Structural and Functional AdaptationsProtists have various adaptations...
868
The Proteasome Structure
1.2K
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...
1.2K
The Proteasome
9.4K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
9.4K
The Proteasome
1.3K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.3K
